Neurocrine Biosciences Executives to Present at Key Investor Conferences in June
Event summary
- Neurocrine Biosciences executives will participate in two investor conferences in June 2026.
- Fireside chat at William Blair's Growth Stock Conference on June 2, 2026, at 10:40 AM CT.
- Fireside chat at Goldman Sachs' Global Healthcare Conference on June 9, 2026, at 9:20 AM ET.
- Webcasts will be available on Neurocrine's website and archived for one month.
The big picture
Neurocrine Biosciences' participation in high-profile investor conferences underscores its focus on engaging with the investment community amid a robust pipeline of treatments for under-addressed neurological and psychiatric disorders. The company's strategic positioning in the biopharmaceutical sector, particularly through collaborations like AbbVie, will be a key area of interest for analysts and investors.
What we're watching
- Pipeline Updates
- How Neurocrine will discuss progress in its mid- to late-phase clinical pipeline.
- Market Positioning
- Whether Neurocrine can reinforce its leadership in neurological and psychiatric disorders.
- Collaborative Strategy
- The impact of AbbVie collaboration on Neurocrine's growth prospects.